Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater ...
The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance coverage. That should change both health outcomes and the way Americas buy and ...
This is the third FDA approval for Omvoh this year, following approvals for Crohn's disease and a citrate-free formulation INDIANAPOLIS, Oct. 27, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) ...
Drugmaker Eli Lilly is significantly lowering the prices of the two lowest doses of its blockbuster weight loss drug Zepbound, it said Tuesday, in a move to expand access and ease supply constraints.
It’s the latest move in the race by drug companies to corner more of the highly lucrative obesity drug market.
Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli Lilly.
The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...
Oct 13 (Reuters) - South Africa's Aspen Pharmacare (APNJ.J), opens new tab said on Monday it had secured regulatory approval to market Eli Lilly's (LLY.N), opens new tab blockbuster diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback